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Supplementary Experimental Procedures: 1 
1.1 Cell culture exposed to DNA methyltransferase inhibitors 2 
Cell lines were maintained in RPMI 1640 supplemented with 10% heat-inactivated 3 
FBS, penicillin G (50 units/ml), and streptomycin (50 μg/ml) in a humidified incubator 4 
containing 5% CO2 in air. The DNA methyltransferase inhibitors (DNMT-is), decitabine 5 
(Dac) and zebularine (Zeb) (Sigma-Aldrich-Japan, Tokyo, Japan), were dissolved in 6 
phosphate-buffered saline. To adjust the biological effects of Dac and Zeb, we analyzed 7 
their growth suppressive effects in 5 AML cell lines categorized in the MPOa-L group 8 
(KG-1, KG-1a, THP-1, CMK-86, and K562). A total of 5 × 105 cells were seeded on 9 
day 0, media containing DNMT-is were freshly added on days 1 and 3, and cells were 10 
harvested on day 5, as previously described [1]. The final concentrations of Dac in the 11 
cultures were 0.3, 1.0, 3.0, and 10.0 μM; those of Zeb were 10.0, 20.0 50.0, and 100.0 12 
μM. The number of viable cells was determined daily by the exclusion of Trypan blue. 13 
DNMT-is inhibited cell proliferation in dose- and time-dependent manners in all cell 14 
lines tested. The exposure to Dac at 1.0 μM and Zeb at 50.0 μM led to comparable 15 
growth suppression in MPOa-L AML cell lines cultures at day 5 (Figure S1d). To assess 16 
the DNA-hypomethylating activity of Dac and Zeb, the methylation status of the 5’ 17 
region of the MPO gene was quantified by bisulfite sequencing. Demethylation was 18 
1 
present at 1.0 μM of Dac and 50.0 μM of Zeb in all 5 AML cell lines with MPOa-L. On 1 
the basis of these results, 1.0μM of Dac and 50.0 μM of Zeb were considered 2 
biologically equivalent in this study for these 5 AML cell lines.  3 
 4 
1.2 Flow cytometry analysis 5 
The expression of cytoplasmic MP) protein was examined using flow cytometry 6 
(FACSCalibur flow cytometer and Cellquest software, BD Biosciences). The antibody 7 
against MPO conjugated with FITC (DAKO) was used after th fixation and 8 
permeabilization of cells using FIX&PERM cell permeabilization reagents (Invitrogen, 9 
Carlsbad, CA, USA) following the manufacturer’s protocol.  10 
 11 
1.3 Direct sequencing of FLT3, NPM1, and CEBPA genes 12 
Mutations in the FLT3, NPM1, and CEBPA genes were detected by direct sequencing 13 
after the amplification of genomic DNA by PCR. The exons tested were as follows: 14 
FLT3, exons 14 and 15; NPM1, exon 12; CEBPA, exon 1. The primers for sequencing 15 
were previously described (see Table below) [2-4]. DNA sequencing of exons was 16 
performed as follows. PCR reactions were run in a final volume of 50 μL containing 10 17 
ng template DNA, 5× buffer,  0.2 mmol/L of each deoxynucleotide triphosphate, 18 
2 
primers (0.3mmol/L of each), nucleotides (0.2 mmol/L of each), and 1 U of 1 
KOD-Plus-Neo polymerase (TOYOBO, Osaka, Japan). The mixture was initially heated 2 
at 94°C for 2 min before being subjected to 35 cycles of denaturation at 94°C for 10 s 3 
and annealing and extension at 68°C for 1 min. The amplified products were 4 
fractionated by gel electrophoresis (1.2% agarose gel), cut from the gel, and purified 5 
with the MinElute Gel extraction kit (QIAGEN, Germany). To screen gene mutations, 6 
PCR products were sequenced in both directions with the previously published primers, 7 
using the BigDye Terminator v3.1 Cycle Sequencing Kit and ABI Prism 3100 ×1 8 
Genetic Analyzer (Applied Biosystems, CA, USA). Heterozygous or homozygous 9 
mutations in NPM1 and CEBPA genes were confirmed by cloning PCR products using 10 
the StrataClone Blunt PCR Cloning Kit (Stratagene, CA, USA) following the 11 
manufacturer’s recommendations. Plasmid DNA was prepared using a QIAprep spin 12 
plasmid miniprep kit (Qiagen, Hilden, Germany), and its integrity was confirmed by the 13 
sequence of both strands using T3 and T7 primers. 14 
 15 
1.4 Quantitative reverse transcriptase-polymerase chain reaction MPO and 16 
DNMT3B genes 17 
Quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) was 18 
3 
performed using LightCycler TaqMan Master (Roche Diagnostics, Mannheim, 1 
Germany) following the manufacturer’s instructions. PCR amplification was performed 2 
using a LightCycler 350S instrument (Roche). Thermal cycling conditions were as 3 
follows; 10 min at 95°C, followed by 45 amplification cycles at 95°C for 10 seconds, 4 
60°C for 30 seconds, and 40°C cooling cycle for 30 seconds. These primers for 5 
DNMT3B could detect 6 alternative spliceoforms; 3 catalytic forms (3B1, 3B2, and 6 
3B6) and 3 non-catalytic forms (3B3, 3B7, and 3B8). Primers and the TaqMan probe for 7 
the sequence of the ABL1 gene were those published in the EAC network protocol for 8 
RQ-PCR [5]. 9 
 10 
1.5 Bisulfite sequencing for the 5’ region of the MPO gene 11 
 Genomic DNA (1μg) was chemically modified with the Cells-to-CpG Bisulfite 12 
Conversion Kit (Applied Biosystems) according to the manufacturer’s 13 
recommendations. Bisulfite-treated DNA was amplified in PCR with MPO-specific 14 
primers. PCR reactions were run in a final volume of 50 μL containing 100 ng DNA, 15 
10× buffer,  2.5 mmol/L of each deoxynucleotide triphosphate, primers (0.2 mmol/L of 16 
each), MgCl2 (25 mmol/L of each), and 2.5 U of TaKaRa EpiTaq HS (TaKaRa, Ohtsu, 17 
Japan). The mixture was initially heated at 95°C for 3 min, before being subjected to 49 18 
4 
cycles of denaturation at 95°C for 1 min, annealing at 55°C for 2 min, and extension at 1 
72°C for 2 min. The amplified products were gel-purified using the MinElute Gel 2 
extraction kit (QIAGEN, Germany) and ligated into the pMD20T-Vector using the 3 
Mighty TA-cloning Kit (TaKaRa). Eighteen to thirty clones per sample were sequenced 4 
using the BigDye Terminator v3.1 Cycle Sequencing Kit and ABI Prism 3100 ×1 5 
Genetic Analyzer. Analysis of the obtained sequences confirmed a complete bisulfite 6 
reaction in all samples. The average methylation of the MPO promoter fragment was 7 
assessed by the Student t-test. 8 
 9 
1.6 Pyrosequencing for long interspersed nuclear element-1 10 
 DNA methylation (%5-mC) of long interspersed nuclear element-1 (LINE-1) was 11 
quantified using PCR-pyrosequencing of the bisulfite-treated DNA (EpigenDx 12 
Laboratory Service (Worcester, MA)), as previously described [6]. In brief, 13 
bisulfite-treated DNA was amplified by PCR using primers designed toward a 14 
consensus LINE-1 sequence. PCR was performed in a 50μL reaction mixture containing 15 
25μL GoTaq Green Master mix (Promega, Madison, WI, USA), 1 pmol of the forward 16 
and biotinylated reverse primers, 50 ng of bisulfite-treated genomic DNA, and water. 17 
Biotin-labeled final PCR products (amplified by biotin-labeled primers) bound to 18 
5 
Streptavidin Sepharose HP (Amersham Biosciences, Uppsala, Sweden) were washed 1 
using the Pyrosequencing Vacuum Prep Tool (Pyrosequencing Inc., Westborough, MA, 2 
USA), as recommended by the manufacturer. A total of 0.3μM of the pyrosequencing 3 
primer was then annealed to the purified single-stranded PCR products, and 4 
pyrosequencing was performed using the PSQ-HS 96 Pyrosequencing System 5 
(Pyrosequencing Inc.). The relative 5-mC content was expressed as a percentage of 6 
methylated cytosines divided by the sum of methylated and unmethylated cytosines 7 
(5-mC / [5-mC + unmethylated cytosine] = %5-mC). Built-in controls were used to 8 
verify bisulfite conversion efficacy. To increase precision, each sample was tested four 9 
times for LINE-1 methylation, and the mean of 4 independent experiments was used in 10 
statistical analyses. The coefficient of variation (CV) among 48 blinded replicate 11 
samples was 5.7%, and the inter-plate CV was 2.9%. Differences in the percentage of 12 
DNA methylation (%5-mC) of LINE-1 among patients in different categories (MPOa-H 13 
group, MPOa-L group, Ph+ALL group, and healthy donor group) were compared using 14 
the non-parametric Kruskal-Wallis test and followed by Dunn’s multiple comparison 15 
post-test. 16 
 17 
1.7 Primer Sequences 18 
6 
Primers for direct sequencing 1 













Primers for the quantitative reverse transcriptase-polymerase chain reaction 3 








probe 5’- TGAACAGCCCCAGTGCCACCAGTTTG-3’ 
ABL1 
forward 5’- GATACGAAGGGAGGGTGTACCA-3’ 
reverse 5’- CTCGGCCAGGGTGTTGAA -3’ 
probe 5’- TGCTTCTGATGGCAAGCTCTACGTCTCC-3’ 
 4 
Primers for bisulfite sequencing 5 





Primers for pyrosequencing 7 
7 
Target Primer Sequencing 
LINE-1 
forward 5’-TTTTGAGTTAGGTGTGGGATATA-3’ 
reverse 5’- biotin-AAAATCAAAAAATTCCCTTTC-3’ 
 1 
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Figure S1 8 
(a) DNA methylation status of the MPO gene promoter in 10 hematological cell lines. 9 
Methylation of the cytosine-phosphate-guanine (CpG) dinucleotide was assessed by 10 
sequencing the multiple cloned alleles of PCR products on bisulfite-treated genomic 11 
DNA. Each horizontal line represents an individual allele. Filled circles represent 12 
methylated CpG sites; open circles, unmethylated CpG sites. The position of each 13 
cytosine nucleotide relative to the transcriptional start site is indicated at the top. 14 
Kasumi-1 and SKM-1 showed high MPO enzymatic activity (MPOa-H), whereas the 8 15 
other cell lines had low MPO enzymatic activity (MPOa-L). 16 
(b) Effects of the DNMT-i treatment on methylation of the 5’ promoter region of the 17 
MPO gene.  18 
9 
Open squares, represent the percentage of methylated CpG sites in the MPO gene of 1 
each cell line without the DNMT-i treatment; filled squares, with the decitabine (Dac) 2 
treatment; gray squares, with the zebularine (Zeb) treatment. 3 
(c) Induction of the MPO protein by the treatment with DNMT-i. 4 
The shared histogram shows the level of intracellular MPO as measured in flow 5 
cytometry. The black curves represent each cell line without the DNMT-i treatment as 6 
the control; gray curves, with the DNMT-is treatment. 7 
(d) Inhibitory effect of DNMT-is on cell proliferation.  8 
A total of 5 × 105 cells were cultured in the presence or absence of Dac (1.0 μM) and 9 
Zeb (50.0 μM). The number of living cells after 5 days was counted by the Trypan blue 10 
dye exclusion method. Error bars indicate one standard deviation (three replicate 11 
experiments). 12 
 13 
Figure S2 14 
DNA methylation status of the MPO gene promoter in CD34-positive cells obtained 15 
from 15 AML patients. CpG dinucleotide methylation was assessed by sequencing 16 
multiple cloned alleles obtained from PCR on bisulfite-treated genomic DNA. 17 
Numbers on the left of each figure show the percentage of MPO positive blasts on 18 
10 
bone marrow smears. MPOa-H and -L indicate a high percentage (>50%) and low 1 
percentage (≤50%) of MPO-positive myeloblasts, respectively. 2 
 3 
Figure S3 4 
Methylation levels of LINE-1 in clinical samples.  5 
LINE-1 methylation was determined as a surrogate for global methylation in 6 
CD34-positive cells from clinical samples (i.e. MPOa-H AML, MPOa-L AML, 7 
Ph+ALL, and healthy donor groups). No significant differences were observed in the 8 
median levels (horizontal dotted line) between the MPOa-H AML group and other 9 









Table S1  Expression of MPO and FLT3, NPM1, and CEBPA Mutations in cell lines 1 





FLT3-ITD NPM1 CEBPA 
SKM-1 Myeloid leukemia - 137.45  Positive Negative wt wt 
Kasumi-1 Myeloid leukemia RUNX1-RUNX1T1 293.65  Positive Negative wt wt 
KG-1 Myeloid leukemia - 0.03  Negative Negative wt wt 
KG-1a Myeloid leukemia - 0.01  Negative Negative wt wt 
THP-1 Monocytic leukemia - 0.54  Negative Negative wt wt 
CMK-86 Megakaryoblastic leukemia - 0.01  Negative Negative wt Single mutation 
K562 Erythroblastic leukemia BCR-ABL1 0.00  Negative Negative wt wt 
CML-T1 T-cell leukemia BCR-ABL1 0.72  Negative Negative wt wt 
BV173 B-cell leukemia BCR-ABL1 0.01  Negative Negative wt wt 
SU-DHL-6 B-cell lymphoma - 0.00  Negative Negative wt wt 
Abbreviations: MPO represents myeloperoxidase; wt, wild type. 2 
Quantitative analysis of MPO and ABL1 mRNA was performed by quantitative reverse-transcriptional PCR amplifications after RNA isolation and complementary 3 
DNA synthesis. MPO enzymatic activity was evaluated using the diaminobenzidine method. The mutation status of FLT3, NPM1, and CEBPA was determined 4 











1 0.072  
2 0.026  
3 0.018  
4 0.093  
5 0.003  
6 0.081  
7 0.033  
8 0.057  
9 0.074  
10 0.044  
11 0.352  
12 0.153  
13 0.085  
14 0.030  
15 0.045  







































































Figure S3 1 
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